Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma:Real-life Data on Liver Disease,Treatment and Prognosis

作     者：Xavier Adhoute Olivia Pietri Guillaume Pénaranda Thomas Wolf Patrick Beaurain Olivier Monnet Arthur Laquière Justine Bonomini Frédéric Neumann Olivier Levrel Jean-Pascal Buono Xavier Hanna Paul Castellani HervéPerrier Marc Bourliere Rodolphe Anty 

作者机构：Department of Gastroenterology and HepatologyHôpital Saint-JosephMarseilleFrance Department of BiostatisticsAlphaBio-Biogroup LaboratoryMarseilleFrance Department of RadiologyHôpital Saint-JosephMarseilleFrance Department of Clinical ResearchHôpital Saint-JosephMarseilleFrance MedipathEguillesFrance Department of Hepatobiliary SurgeryHôpital Saint-JosephMarseilleFrance Department of Gastroenterology and HepatologyHôpital Universitaire de l’ArchetNiceFrance 

出 版 物：《Journal of Clinical and Translational Hepatology》 (临床与转化肝病杂志（英文版）)

年 卷 期：2023年第11卷第5期

页      面：1106-1117页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

主　　题：Intrahepatic cholangiocarcinoma Hepatocellular carcinoma Cirrhosis NASH Oncogenic alterations 

摘      要：Background and Aims:Hepatocellular carcinoma(HCC)and intrahepatic cholangiocarcinoma(iCCA)have common features and *** real-life study investigated their characteristics,treatment modalities,and ***:This retrospective comparative study was performed in 1,075 patients seen at one tertiary center between January 2008 and December *** survival(OS)was estimated by the Kaplan-Meier *** of iCCAs after histological and radiological review,and molecular profiling was ***:HCCs patients were more likely to have early-stage disease than iCCA *** patients were more likely to be female,especially those patients without cirrhosis(43%vs.17%).Cirrhosis was prominent among HCC patients(89%vs.34%),but no difference in underlying liver disease among cirrhotic patients was *** of HCC patients was 18.4(95%CI:6.4,48.3)months,that of iCCA patients was 7.0(95%CI:3.4,20.1)*** of Barcelona Clinic Liver Cancer C HCC patients was 7.8(95%CI:4.3,14.2)months,that of advanced/metastatic iCCA patients was 8.5(95%CI:5.7,12.3)*** patients treated with sorafenib,OS was longer in HCC patients who received subsequent tyrosine kinase inhibitor *** significant OS difference was found between iCCA patients with and without cirrhosis or according to histological subtype.A targetable molecular alteration was detected in 50%of the iCCA ***:In this French series,cirrhosis was common in iCCA,which showed etiological factors comparable to those of HCC,implying a distinct oncogenic *** entities had a dismal prognosis at advanced ***,systemic therapies sequencing in HCC and molecular profiling in iCCA offer new insights.